Statistically significant (p < 0.005) differences in levels of MAGE-A3 expression were observed only in guadecitabine- and DAC-treated, compared to untreated hematological cancer cells (Supplementary Table 7). This evidence concerns the gene MAGEA3 and hematopoietic and lymphoid cell neoplasm.